Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

Haematologica. 2016 Dec;101(12):e485-e487. doi: 10.3324/haematol.2016.151266. Epub 2016 Aug 18.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Bortezomib / administration & dosage*
  • Bortezomib / adverse effects
  • Humans
  • Induction Chemotherapy / adverse effects
  • Induction Chemotherapy / methods
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Peripheral Nervous System Diseases / chemically induced*
  • Risk Factors

Substances

  • Antineoplastic Agents
  • Bortezomib